Adolor to re-acquire full US Entereg rights from GSK
This article was originally published in Scrip
Executive Summary
Adolor is to re-acquire all rights to Entereg (alvimopan) from GlaxoSmithKline for $25 million. The product, which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis, is currently co-promoted by the companies in the US.